ArticleEuropean journal of public health2022
Primary COVID-19 vaccine cycle and booster doses efficacy: analysis of Italian nationwide vaccination campaign.
Article in European journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Balancing strategies in vaccination and mask-wearing for Chinese medical staff in post-COVID-19 era: a modelling study and cost-effectiveness analysis.Journal of global health · 2025Article
- Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.iScience · 2024Article
- The spatial-temporal variations and influencing factors of COVID-19 case fatality rate: a worldwide study in 30 countries from February 2021 to May 2022.Epidemiology and infection · 2024Article
- Intranasal delivery of a recombinant adenovirus vaccine encoding the PEDV COE elicits potent mucosal and systemic antibody responses in mice.Microbiology spectrum · 2024Article
- Design and analysis heterogeneity in observational studies of COVID-19 booster effectiveness: A review and case study.Science advances · 2023Review
- Serum Anti-Spike Antibodies Are Not Affected by Immunosuppressants in SARS-CoV-2 Vaccinations Given to Brazilian Patients with Inflammatory Bowel Disease.Healthcare (Basel, Switzerland) · 2023Article
- Design and Analysis Heterogeneity in Observational Studies of COVID-19 Booster Effectiveness: A Review and Case Study.medRxiv : the preprint server for health sciences · 2023Article
- Evaluation of residual humoral immune response against SARS-CoV-2 by a surrogate virus neutralization test (sVNT) 9 months after BNT162b2 primary vaccination.Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy · 2023Article
- The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence.Vaccines · 2023Review
- Adolescents' Opinions on COVID-19 Vaccine Hesitancy: Hints toward Enhancing Pandemic Preparedness in the Future.Vaccines · 2023Article
- Different Interventions for COVID-19 Primary and Booster Vaccination? Effects of Psychological Factors and Health Policies on Vaccine Uptake.Medical decision making : an international journal of the Society for Medical Decision Making · 2023Article
- In the Face of a Pandemic: "I Felt the Same as When the War Started"-A Qualitative Study on COVID-19 Vaccine Acceptance in Bosnia and Herzegovina.International journal of public health · 2023Article
- Factors Associated With COVID-19 Non-Vaccination in Switzerland: A Nationwide Study.International journal of public health · 2023Article
- Article
- Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021.Global epidemiology · 2022Article
- Perceived medical care quality during COVID-19 illness links socioeconomic disadvantage to vaccine hesitancy.Preventive medicine reports · 2022Article
- Drivers of the Intention to Receive a COVID-19 Booster Vaccine: Insights from the UK and Australia.Vaccines · 2022Article
- Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose.Vaccines · 2022Article
- Predicting COVID-19 booster vaccine intentions.Applied psychology. Health and well-being · 2022Article
- Impact of BNT162b2 primary vaccination and homologous booster on anti-SARS-CoV-2 IgA antibodies in baseline seronegative healthcare workers.Advances in laboratory medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We provide here an updated analysis of primary COVID-19 vaccination and vaccine booster doses efficacy, emerging from the ongoing Italian nationwide COVID-19 vaccination campaign. Primary COVID-19 vaccination efficacy was 76-92% within 6 months, decreasing to 34-80% after 6 months. Administration of vaccine booster doses decreased SARS-CoV-2 infections by 65%, COVID-19-related hospitalizations and deaths by 69% and 97% compared with vaccine efficacy after 6 months, but also decreased SARS-CoV-2 infections by 39% compared with vaccine efficacy within 6 months. These results suggest that COVID-19 vaccine booster doses are important for restoring vaccine efficacy and further limiting virus circulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.